Markets

AbbVie Receives FDA's Approval For JUVMO To Treat Adults with Parkinson's Disease

Sep 28, 2026 · 08:02 AM ET· updated 1h ago

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with

Why It Matters

AbbVie got permission to sell a new Parkinson's medicine called JUVMO. This shows the company is creating treatments people need, which could help its future business.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABBV264.73

+0.39 (+0.15%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.